Key issues in non-viral gene delivery

Adv Drug Deliv Rev

C. W. Pouton, L. W. Seymour

Research output: Contribution to journalArticleResearchpeer-review

Abstract

The future of non-viral gene therapy depends on a detailed understanding of the barriers to delivery of polynucleotides. These include physicomechanical barriers, which limit the design of delivery devices, physicochemical barriers that influence self-assembly of colloidal particulate formulations, and biological barriers that compromise delivery of the DNA to its target site. It is important that realistic delivery strategies are adopted for early clinical trials in non-viral gene therapy. In the longer term, it should be possible to improve the efficiency of gene delivery by learning from the attributes which viruses have evolved; attributes that enable translocation of viral components across biological membranes. Assembly of stable, organized virus-like particles will require a higher level of control than current practice. Here, we summarize present knowledge of the biodistribution and cellular interactions of gene delivery systems and consider how improvements in gene delivery will be accomplished in the future.
Original languageEnglish
Pages (from-to)3-19
Number of pages17
JournalAdvanced Drug Delivery Reviews
Volume34
Publication statusPublished - 1998

Cite this

@article{0276bdcfb31f4a459425082693315a74,
title = "Key issues in non-viral gene delivery: Adv Drug Deliv Rev",
abstract = "The future of non-viral gene therapy depends on a detailed understanding of the barriers to delivery of polynucleotides. These include physicomechanical barriers, which limit the design of delivery devices, physicochemical barriers that influence self-assembly of colloidal particulate formulations, and biological barriers that compromise delivery of the DNA to its target site. It is important that realistic delivery strategies are adopted for early clinical trials in non-viral gene therapy. In the longer term, it should be possible to improve the efficiency of gene delivery by learning from the attributes which viruses have evolved; attributes that enable translocation of viral components across biological membranes. Assembly of stable, organized virus-like particles will require a higher level of control than current practice. Here, we summarize present knowledge of the biodistribution and cellular interactions of gene delivery systems and consider how improvements in gene delivery will be accomplished in the future.",
author = "Pouton, {C. W.} and Seymour, {L. W.}",
note = "M1 - 1 Pouton Seymour ENG 2000/06/06 Adv Drug Deliv Rev. 1998 Oct 5;34(1):3-19.",
year = "1998",
language = "English",
volume = "34",
pages = "3--19",
journal = "Advanced Drug Delivery Reviews",
issn = "0169-409X",
publisher = "Elsevier",

}

Key issues in non-viral gene delivery : Adv Drug Deliv Rev. / Pouton, C. W.; Seymour, L. W.

In: Advanced Drug Delivery Reviews, Vol. 34, 1998, p. 3-19.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Key issues in non-viral gene delivery

T2 - Adv Drug Deliv Rev

AU - Pouton, C. W.

AU - Seymour, L. W.

N1 - M1 - 1 Pouton Seymour ENG 2000/06/06 Adv Drug Deliv Rev. 1998 Oct 5;34(1):3-19.

PY - 1998

Y1 - 1998

N2 - The future of non-viral gene therapy depends on a detailed understanding of the barriers to delivery of polynucleotides. These include physicomechanical barriers, which limit the design of delivery devices, physicochemical barriers that influence self-assembly of colloidal particulate formulations, and biological barriers that compromise delivery of the DNA to its target site. It is important that realistic delivery strategies are adopted for early clinical trials in non-viral gene therapy. In the longer term, it should be possible to improve the efficiency of gene delivery by learning from the attributes which viruses have evolved; attributes that enable translocation of viral components across biological membranes. Assembly of stable, organized virus-like particles will require a higher level of control than current practice. Here, we summarize present knowledge of the biodistribution and cellular interactions of gene delivery systems and consider how improvements in gene delivery will be accomplished in the future.

AB - The future of non-viral gene therapy depends on a detailed understanding of the barriers to delivery of polynucleotides. These include physicomechanical barriers, which limit the design of delivery devices, physicochemical barriers that influence self-assembly of colloidal particulate formulations, and biological barriers that compromise delivery of the DNA to its target site. It is important that realistic delivery strategies are adopted for early clinical trials in non-viral gene therapy. In the longer term, it should be possible to improve the efficiency of gene delivery by learning from the attributes which viruses have evolved; attributes that enable translocation of viral components across biological membranes. Assembly of stable, organized virus-like particles will require a higher level of control than current practice. Here, we summarize present knowledge of the biodistribution and cellular interactions of gene delivery systems and consider how improvements in gene delivery will be accomplished in the future.

M3 - Article

VL - 34

SP - 3

EP - 19

JO - Advanced Drug Delivery Reviews

JF - Advanced Drug Delivery Reviews

SN - 0169-409X

ER -